title: Highly active antiretroviral treatment for the prevention of HIV transmission.
abstract: In 2007 an estimated 33 million people were living with HIV; 67% resided in sub-Saharan Africa, with 35% in eight countries alone. In 2007, there were about 1.4 million HIV-positive tuberculosis cases. Globally, approximately 4 million people had been given highly active antiretroviral therapy (HAART) by the end of 2008, but in 2007, an estimated 6.7 million were still in need of HAART and 2.7 million more became infected with HIV.Although there has been unprecedented investment in confronting HIV/AIDS - the Joint United Nations Programme on HIV/AIDS estimates $13.8 billion was spent in 2008 - a key challenge is how to address the HIV/AIDS epidemic given limited and potentially shrinking resources. Economic disparities may further exacerbate human rights issues and widen the increasingly divergent approaches to HIV prevention, care and treatment.HIV transmission only occurs from people with HIV, and viral load is the single greatest risk factor for all modes of transmission. HAART can lower viral load to nearly undetectable levels. Prevention of mother to child transmission offers proof of the concept of HAART interrupting transmission, and observational studies and previous modelling work support using HAART for prevention. Although knowing one's HIV status is key for prevention efforts, it is not known with certainty when to start HAART.Building on previous modelling work, we used an HIV/AIDS epidemic of South African intensity to explore the impact of testing all adults annually and starting persons on HAART immediately after they are diagnosed as HIV positive. This theoretical strategy would reduce annual HIV incidence and mortality to less than one case per 1000 people within 10 years and it would reduce the prevalence of HIV to less than 1% within 50 years. To explore HAART as a prevention strategy, we recommend further discussions to explore human rights and ethical considerations, clarify research priorities and review feasibility and acceptability issues.
authors.affiliation: Department of HIV/AIDS, World Health Organization, Geneva, Switzerland. granichr@who.int
authors.forename: Reuben
authors.initials: R
authors.lastname: Granich
authors.forename: Siobhan
authors.initials: S
authors.lastname: Crowley
authors.forename: Marco
authors.initials: M
authors.lastname: Vitoria
authors.forename: Ying-Ru
authors.initials: YR
authors.lastname: Lo
authors.forename: Yves
authors.initials: Y
authors.lastname: Souteyrand
authors.forename: Christopher
authors.initials: C
authors.lastname: Dye
authors.forename: Charlie
authors.initials: C
authors.lastname: Gilks
authors.forename: Teguest
authors.initials: T
authors.lastname: Guerma
authors.forename: Kevin M
authors.initials: KM
authors.lastname: De Cock
authors.forename: Brian
authors.initials: B
authors.lastname: Williams
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D015658:HIV Infections / Q000188:drug therapy* / Q000517:prevention & control* / Q000635:transmission; D006801:Humans
chemical_list: D019380:Anti-HIV Agents